Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Gynecology and Obstetrics, University of Munich, Munich, Germany.
Gynecol Oncol. 2016 Sep;142(3):427-34. doi: 10.1016/j.ygyno.2016.07.009. Epub 2016 Jul 9.
Metastatic vulvar cancer is a rare disease. Information on metastatic patterns and corresponding prognosis or therapeutic approaches is scarce. We therefore analyzed pattern and course of metastatic disease in a large single center cohort.
All patients with primary squamous-cell cancer of the vulvar [n=391, median age: 60years (range 20-94)] treated at the Gynecological Cancer Center Hamburg-Eppendorf 1996-2013 were retrospectively evaluated for occurrence of distant metastasis. Furthermore, a systematic Medline database search was performed using the terms: 'vulvar cancer' AND 'metastasis', 'chemotherapy', 'patterns of recurrence', or 'prognosis'.
Out of 391 patients with primary squamous cell vulvar cancer, 20 patients (5.1%) eventually presented with distant metastases. In these 20 patients, median time to first diagnosis of metastasis after primary diagnosis was 13.4months (range 4-104). Often patients experienced one or more local recurrences before distant spread (12/20, 60.0%). Documented metastatic sites were lung (n=9), liver (n=7), bone (n=5), skin (n=4) and lymph-nodes (axillary/thoracic/paraaortic, n=3). The majority of patients presented with unilocal metastases (13/20, 65.0%). In univariate analysis tumor diameter, invasion depth, nodal status and number of metastatic lymph-nodes were identified predictive for occurrence of distant metastases. 2-year-overall-survival-rate after metastases of all metastatic patients was 11.3%; median survival from first diagnosis of metastases was 5.6months.
The occurrence of distant metastasis from vulvar cancer is a rare event with very limited prognosis. Further efforts, especially translational research will be crucial to identify prognostic markers as well as therapeutic targets to improve survival in these patients.
转移性外阴癌是一种罕见疾病。有关转移模式和相应预后或治疗方法的信息很少。因此,我们分析了大型单中心队列中转移性疾病的模式和过程。
回顾性分析了 1996 年至 2013 年在汉堡-埃彭多夫妇科癌症中心治疗的 391 例原发性外阴鳞状细胞癌患者(中位年龄:60 岁[范围 20-94])发生远处转移的情况。此外,还使用了“外阴癌”和“转移”、“化疗”、“复发模式”或“预后”等术语,对 Medline 数据库进行了系统搜索。
在 391 例原发性外阴鳞状细胞癌患者中,有 20 例(5.1%)最终出现远处转移。在这 20 例患者中,首次诊断远处转移后至首次诊断的中位时间为 13.4 个月(范围 4-104)。通常,在远处转移之前,患者经历了一次或多次局部复发(12/20,60.0%)。记录的转移部位有肺(n=9)、肝(n=7)、骨(n=5)、皮肤(n=4)和淋巴结(腋窝/胸部/腹主动脉旁,n=3)。大多数患者表现为单部位转移(13/20,65.0%)。单因素分析显示,肿瘤直径、浸润深度、淋巴结状态和转移淋巴结的数量与远处转移的发生有关。所有转移性患者的 2 年总生存率为 11.3%;从首次诊断转移到死亡的中位生存时间为 5.6 个月。
外阴癌远处转移的发生是一种罕见事件,预后非常有限。进一步的努力,特别是转化研究,对于确定预后标志物以及治疗靶点以改善这些患者的生存至关重要。